On November 30, 2020 Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) reported that it has completed its conversion into an N.V., a public company under the laws of the Netherlands (naamloze vennootschap, "N.V.") effective from 28 November 2020 (Press release, Vivoryon Therapeutics, NOV 30, 2020, View Source [SID1234571935]). The Company will from that moment operate under the registered name Vivoryon Therapeutics N.V. and its statutory seat will be in Amsterdam, the Netherlands, while the administrative headquarters and the business operations will remain in Germany with locations in Halle (Saale) and Munich. The new legal form has no impact on the Company’s day-to-day operations.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As a consequence of the conversion, the shareholders of Vivoryon Therapeutics AG will automatically become shareholders of Vivoryon Therapeutics N.V.. The shares will be trading under a new ISIN NL00150002Q7. The last trading date of the shares under the ISIN DE0007921835 and the first trading day of the shares under the new ISIN NL00150002Q7 will be announced as soon as possible by a press release . The central securities depository for the shares under ISIN NL00150002Q7 will be Euroclear Nederland (Nederlands Centraal Instituut voor Giraal Effectenverkeer B.V.). Trading in Vivoryon Therapeutics shares will not be affected by the conversion.
Dr. Ulrich Dauer, Chief Executive Officer of Vivoryon Therapeutics N.V., commented: "This conversion into anN.V. reflects the continued international focus of Vivoryon Therapeutics. We are convinced that this corporate transformation will be a gateway to new international investors and may also provide access to additional capital markets, such as the US stock market via an ADR program or a full NASDAQ listing, even though there are currently no specific plans in this regard. We look forward to continuing to execute on our growth strategy with additional opportunities gained by this corporoate conversion."